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Recruitment and Retention of Diverse Populations
in Antiretroviral Clinical Trials: Practical Applications
from the Gender, Race And Clinical Experience Study
Ron Falcon, M.D.,1 Dawn Averitt Bridge,2 Judith Currier, M.D., M.Sc.,3 Kathleen Squires, M.D.,4
Debbie Hagins, M.D.,5 Deborah Schaible, Pharm.D.,1 Robert Ryan, M.Sc.,6 and Joseph Mrus, M.D., M.Sc.,1
on behalf of the GRACE Study Group

Abstract

Background: Women, particularly women of color, remain underrepresented in antiretroviral (ARV) clinical
trials. To evaluate sex-based differences in darunavir/ritonavir-based therapy, the Gender, Race And Clinical
Experience (GRACE) study was designed to enroll and retain a high proportion of women representative of the
racial/ethnic demographics of women with HIV/AIDS in the United States. The recruitment and retention
strategies used in GRACE are described in this article.
Methods: Recruitment and retention strategies targeting women included selecting study sites that focused on
women, involving community consultants, site-specific enrollment plans, access to other ARV drugs, study
branding, site and patient toolkits, targeted public relations, site grants for patient support, and subsidized child
care and transportation.
Results: The recruitment strategies were successful; 287 (67%) women were enrolled, primarily women of color
(black, n = 191 [67%], Hispanic, n = 60 [21%]). Despite the focus on retention, a greater proportion of women
(32.8%) discontinued compared with men (23.2%).
Conclusions: The successes of GRACE in enrolling a representative population of women were rooted in pretrial
preparation, engagement of community advisors, enrollment quotas, choice of study sites and site support.
Lessons learned from GRACE may be applied to future study design. Further focus on factors that influence
discontinuation is warranted.

Introduction

A

pproximately 25% of new HIV diagnoses in the United States are in women,1–3 and the rate of these new
infections has been increasing steadily over the past decade.4
Women of color are disproportionately affected; black and
Hispanic women constitute 25% of the women in the United
States, yet in 2008, black and Hispanic women accounted for
an estimated 80% of new HIV/AIDS diagnoses in this patient
population.1,2,5 Despite this increase, women, particularly
those who are treatment experienced, remain underrepresented in clinical trials of antiretroviral (ARV) agents for HIV.6

Consequently, current treatment guidelines are based primarily on data from clinical trials that predominantly enrolled
men.
Although data are limited on sex-based differences in HIV
therapy, the results of some studies that have made gender
comparisons (albeit with limited numbers of women) have
suggested that there may be differences between women and
men in the pharmacokinetics, efficacy, and safety of ARVs.4,7,8
In contrast, post hoc analyses of several other studies have not
identified sex-based differences in the efficacy and safety of
ARV therapy; however, these studies were not designed
for sex-based comparisons.9–11 Although the number of
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treatment-naı̈ve women enrolled into clinical trials has been
steadily increasing, recruitment and retention of treatmentexperienced women in trials have been less successful.4,9,12
Clinical trials that are specifically designed to recruit and retain a sufficient number of HIV-infected women will ensure
that studies are adequately powered for between-sex comparisons and provide meaningful data on the effects of ARVs
in women.
There are many barriers to the successful recruitment and
retention of women in clinical trials. Typically, women occupy primary care roles in their families and may place family
commitments above their own personal medical care.13 Additional factors for some women that may impact regular
access to healthcare and lead to missed medical appointments
include domestic violence or the threat of violence, use of
illicit drugs, and perceived stigma about their HIV status.13
To overcome these barriers and achieve successful participation of women in clinical trials, innovative approaches to trial
design and conduct are required.
The Gender, Race, And Clinical Experience (GRACE) study
was specifically designed to enroll a high proportion of women in order to investigate sex-based differences in ARV
therapy. An array of approaches and strategies, some of them
novel, were applied in GRACE in an effort to maximize recruitment and retention of women. GRACE successfully enrolled 67% women, thereby challenging the collective
sentiment that such a goal could not be accomplished. As
individual patient’s motivations for participation in the trial
were not investigated, it was not possible to determine the
relative effectiveness of the independent recruitment and retention tactics. The focus of this article is a review of the enrollment strategies that were applied, the challenges faced
with retention of women, and the key lessons learned
throughout the planning and conduct of the study.
Materials and Methods
Study design, implementation, and conduct
The GRACE study was specifically designed to compare
the efficacy, incidence of adverse events, and tolerability over
48 weeks of darunavir/ritonavir (DRV/r) 600 mg/100 mg
twice daily combined with an investigator-selected optimized
background regimen in ARV-experienced women and men.
This open-label, phase 3b study was conducted at 65 sites
across the United States, Puerto Rico, and Canada.
Pretrial planning
Early in protocol development, the study sponsor, Tibotec
Therapeutics, partnered with clinicians, researchers, and
community advisors for input into the planning of a womenfocused study. The study design was not preconceived, although the sponsor envisioned a study in women that would
expand the current knowledge base for the protease inhibitor,
DRV. Initially, the study sponsor hosted a 2-day internal
brainstorming session to discuss issues that might have an
impact on GRACE, including where to find study sites and
how to motivate women to participate in the trial. The sponsor also examined the outcomes of previous trials for strategies and tactics that could be applied to this study.
A series of advisory boards was subsequently hosted with
treatment advocates, researchers, and clinicians involved in
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the care of women. Advisors provided insight into the needs
of women and the goals and unique challenges of conducting
a study in this population. The discussion included potential
confounding baseline factors that could influence study design, implementation, or outcomes, such as variations in care;
differences in access to medications; differences in the experience level of the study site or principal investigator (PI);
presence or absence of support personnel, such as social
workers or peer advocates; and an affiliation of the study site
with an AIDS Service Organization. The study concept, details, and protocol were refined during additional advisory
boards held over several months before the start of the study.
Study population and enrollment
All inclusion and exclusion criteria were reviewed for the
potential to serve as a barrier to participation for women or
people of color, and adjustments were made as necessary. No
CD4 + count criterion was imposed, prior treatment allowances were broad, enrollment of patients on treatment interruptions of at least 4 weeks was allowed, and investigators
were permitted to enroll patients actively using illicit drugs or
alcohol if they believed the patient could comply with the
study protocol. Full inclusion and exclusion criteria have been
described.14 The sample size was determined based on a
noninferiority model, a hypothesized, clinically relevant difference in response rates between women and men (15%) and
80% statistical power, with an allowance for discontinuations.
Women were ultimately overrepresented to allow greater
insight into safety and tolerability in this population.
Site selection and engagement
The site selection process considered epidemiologic trends,
as women with HIV/AIDS are not evenly distributed across
the United States.2 Almost 50% of selected sites were in the
southeastern United States,15 reflecting the higher concentration of HIV/AIDS among black and Hispanic women in
this region (Fig. 1). Moreover, guidance received during the
planning stage recommended that the study sponsor identify
sites where women receive HIV primary care and have preestablished relationships with healthcare providers. It was
hoped that use of primary care sites would foster a strong
commitment to GRACE on behalf of both provider and patient, minimize the travel and time burden associated with
clinical care, and aid patients in overcoming the challenges to
continued trial participation. Thus, the study sponsor did not
limit participation to sites with extensive prior experience in
conducting clinical trials, but instead broadened site recruitment to include centers that had strong community relationships, could support flexible office hours, and had the
capacity to and interest in exceeding the standards of care
for their female patients. Community advisors provided an
additional list of more than 30 possible study sites and
reached out to women in their communities to identify
women-focused healthcare providers. The ability of each site
to conduct a successful trial was assessed using a feasibility
questionnaire that was specifically modified to assess issues
important for GRACE. Following initial evaluation, in-person
site feasibility visits were used to confirm the appropriateness
of sites.
In all, eight novel sites with a focus on women but with
limited clinical trial experience participated in GRACE. Most
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FIG. 1.
study.
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Study sites and geographical distribution of women enrolled in the Gender, Race And Clinical Experience (GRACE)

novel study sites were paired with more experienced sites for
support and guidance throughout the study. These new sites
had to be trained by the sponsor on Good Clinical Practices,
monitored more closely on an ongoing basis, and visited more
frequently by field clinical personnel and consultants to assist
with enrollment strategies and data collection. Unlike in other
clinical trials, the Clinical Research Organization (CRO) was
afforded special monitoring rights that enabled it to visit sites
and provide support when required.
Investigator meeting
After identification of the participating study sites and
before study initiation, a meeting brought together investigators, study coordinators, community advisors, the GRACE
Study Team, and the study sponsor. Various sessions included HIV-positive women sharing their experiences of living with HIV and participating in clinical trials, protocol
review, site questions and feedback, identification of potential
challenges at the site level, and brainstorming about tools or
tactics for success. In small group sessions, each site was required to draft an action plan for site outreach. This meeting
also allowed sites that were new to clinical research an opportunity to network with each other and with more experienced clinical sites.
Community advocates as consultants
A patient advocate with significant personal and professional experience working with women living with HIV/
AIDS was hired as a consultant for GRACE. This consultant

provided important input to the study sponsor in all aspects
of study design and implementation. Significant emphasis
was placed on providing study sites with direct and frequent
access to the consultant for various types of assistance.
Moreover, the consultant worked to schedule meetings with
community-based groups, connect study sites with local resources, and conduct specialized GRACE presentations to
community groups, such as the Southern AIDS Coalition. A
second community consultant who served as an advisor
during the early planning stages was later enlisted to assist
with study recruitment, primarily in the Los Angeles area.
Recruitment and retention strategies
Discussions during pretrial planning with the consultant
led to the application of several novel tactics for study recruitment. First, each site was initially required to enroll at
least 3 women before enrolling a man, and thereafter each site
was required to maintain at least 70% female enrollment.
Because it was expected that the majority of women participating in GRACE would be black or Hispanic, the enrollment
of white men was limited to 25% of the total planned population of men to promote a similar racial/ethnic distribution
between sexes for meaningful statistical comparisons.
Second, the name GRACE, created by the consulting patient advocate, was designed to appeal to women. The decision to brand GRACE with a unique multicolored butterfly
logo subtly intertwined with women’s silhouettes (Fig. 2) to
give the study an identity was conceived during the advisory
process and was received with enthusiasm by both women
and their healthcare providers. The logo was designed in
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FIG. 2. The GRACE logo for unique branding over the
course of the study.

partnership with the community consultant to represent diversity, community, and a connectedness that transcends the
common dividing lines of race, socioeconomic status, and
geography. Even the script font was chosen specifically to
appeal to women. The GRACE logo became the backbone of
study-related materials, allowing the study to resonate with
physicians and patients at a personal level and, as such, was
an essential component of study outreach.
In addition to the recruitment approaches mentioned and
unlike many other ARV studies, the launch of GRACE also
included comprehensive and targeted media and community
outreach in communities of color. The goals of the media and
community outreach, which was designed as a public relations campaign rather than paid advertising, were to raise
public awareness of, generate excitement for, and facilitate
enrollment of women of color into the study. Black and Hispanic media outlets in local markets were targeted in both
English and Spanish. A diverse array of media was used, including print advertisements, public service announcements,
community list-serves, newsletters, and faith-based forums.
Television spots, news stories, and live radio interviews were
used where possible, and HIV treatment press was enlisted to
help disseminate the study plan to specific communities of
color. These efforts were continued throughout the trial, engaging patients who may not normally have access to information regarding the conduct and availability of clinical trials.
The recruitment of a large proportion of underrepresented
women of color was a key goal in GRACE, but the retention of
trial participants was another critical objective. Thus, strategies intended to foster retention of women also were incorporated into the trial design. A stipend for child care services
and transportation to trial sites was offered to all participants
to reduce barriers and encourage ongoing clinical care visits.
Although transportation support is included in many trial
protocols, it is not often publicized to the site staff or patients.
Thus, significant efforts were made within GRACE to communicate that these resources were available, and all prospective participants were made aware, via the informed
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consent form, of the stipend for child care services or transportation costs.
Modest site grants were available to fund activities that
would foster the retention of patients. In all, 12 of 65 sites
applied for and received grants to support activities, such as
clinic-based support groups, lunch and learns, and other educational programs. The goal of these retention activities was
to foster a sense of connectedness and support in a place
where women could learn more about the study. Additionally, women could discuss and share their perceptions
and concerns about clinical trial participation and general
challenges related to HIV and its management. Some sites also
provided more frequent and personal access to physicians
and nurses, which allowed for flexibility in clinic attendance
and facilitated a reduction in potential barriers to continued
trial participation. Other sites offered prefilled pillboxes,
pillbox storage/refrigeration, or individual reminders for
scheduled visits in order to simplify some of the practical
aspects of disease management that can contribute to the
discontinuation of care. Staff from at least one study site
conducted home visits as unique circumstances for individual
patients arose.
Although most strategies were used solely for either recruitment or retention purposes, some tactics were employed
for both. The provision of several ARVs, including an investigational agent to facilitate construction of a full treatment
regimen, helped eliminate any potential barriers to accessing
medication. This approach also served to differentiate
GRACE from other clinical trials for treatment-experienced
patients. In addition, toolkits were used as both a recruitment
and a retention strategy. Institutional Review Boardapproved kits were designed based on feedback from community and physician advisors, as well as ideas generated
by site staff at the investigator meeting, and were branded
only with the GRACE study logo or components of that logo
to identify the materials. The outreach toolkits included
GRACE posters and fliers, inclusion/exclusion cards for
providers, a booklet on engaging women in clinical trials,
‘‘Ask me about GRACE’’ buttons for site staff, and GRACE
balloons for outreach events. A CD-ROM with templates for
fliers and advertisements, draft public service announcements, a ‘‘Dear Colleague’’ letter for the purpose of piquing
interest among colleagues in the local area, and a supplemental grant request form were also included. The patient
toolkits included a branded canvas bag containing a day
planner, GRACE pen, water bottle, single-dose pillbox, site
contact card, insulated lunchbox, and a description of study
visits and procedures. Acknowledgment certificates, intended
for patients, site staff, and partners in the local community,
were used to recognize individual contributions to the study,
and GRACE birthday cards gave sites a mechanism to celebrate and recognize their patients as people rather than solely
as study participants.
Results
Impact of recruitment and retention strategies
The novel recruitment strategies employed in GRACE were
successful; the recruitment goals were met on time. A total of
429 patients were recruited to the trial, including 287 (67%)
women, most of whom were women of color (black, n = 191
[67%], Hispanic, n = 60 [21%]).14 The ability of the GRACE
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study to provide meaningful information about women with
HIV hinged on the mandated enrollment of at least 70% women at each study site. This strategy proved to be highly effective, as approximately halfway into recruitment, only 10%
of the participants were men. At that point, the enrollment
requirement was discontinued to assure that enough men
would participate to meet the study goals. Of the 65 sites, a
total of 59 enrolled patients within the enrollment time line,
and only 1 site closed during the study period. Patients were
not required to document their motivation for participating in
the study at the time of enrollment, so it was difficult to
quantify the impact of individual enrollment strategies.
However, some patients did specifically request to participate
in the study as a result of the media campaigns.
An interim analysis of GRACE revealed that among the
first 200 patients enrolled, nearly 25% of women had discontinued the study through week 24. Before the availability
of the interim analysis, the main focus of the study team and
sites was on recruitment of women. At this point, efforts
shifted to reducing subsequent discontinuations among
GRACE participants. The team reviewed all discontinuations
for trends in causes or patient/site characteristics, but the
review did not reveal any consistent trends or clear opportunities for additional interventions. From that point forward,
however, the study team and sites committed to trying to
improve the retention rate for women.
Among the 429 patients who ultimately enrolled in the
study, a significantly greater proportion of women discontinued the trial vs. men (32.8% vs. 23.2%, respectively,
p < 0.05) (Fig. 3) before the final week 48 visit.14 The higher
rate of discontinuation among women in the GRACE trial was
driven by reasons other than a lack of response to study
medication; only 6 (2.1%) women discontinued because of
virologic failure. Instead, the primary reasons for study discontinuation among women were loss to follow-up, adverse

FIG. 3. Study disposition. *Other classification was selected
by the investigator as reason for discontinuation. (From
Currier J, et al. Ann Intern Med 2010;153:349–357.14 Reprinted
with permission. Copyright 2010 The American College of
Physicians.)
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events, and reasons categorized as ‘‘other’’ by the study investigator (e.g., site closed, patient moved, pregnancy). The
rate of discontinuation due to adverse events was slightly
higher for women than men (Fig. 3). In addition, rates of
discontinuation in GRACE were also higher in black patients
(32.6%) vs. white (26.2%) or Hispanic (24.0%) patients. Individual study sites likely applied different tactics to improve
study retention based on the resources available to them, but
the relative success or failure of individual tactics was not
tracked.
Interestingly, novel study sites were more successful in
recruitment of trial participants and also had somewhat better
retention in the study compared with other sites. The novel
sites recruited an average of 2 more patients per site to the
study and had a discontinuation rate 33% lower than other
sites (overall discontinuation rates of 21% at novel sites vs 33%
at other sites).
Discussion
Although it is difficult to assess the individual contributions
of the many recruitment and retention techniques employed in
GRACE, in retrospect, we believe that the two most important
components of the study plan were early engagement of experienced, passionate clinicians and community advocates,
and thoughtful identification and selection of study sites. The
researchers and community advisors were dedicated partners
in the GRACE study, with a vested interest in successfully
generating ARV treatment data in women. Their input
throughout the study was indispensible in designing a successful trial that would fulfill the goals of all participating
parties. Equally as important as the involvement of these advisors was the decision to include novel sites with limited
clinical trial experience but with ready access to the population
of interest—women. Novel sites not only proved to be successful in recruitment but also had somewhat better retention
in the study, thus demonstrating that such sites are fully capable of conducting clinical trials if provided with appropriate
support. An indirect, but important, outcome of the engagement of novel study sites was enhancing the capacity of these
sites to conduct future clinical trials; several of these sites have
since successfully participated in other ARV studies.
In general, provision of individualized consulting support
for sites proved to be important to the overall success of the
trial and to study recruitment in particular. Because challenges at each site were unique, the support provided was
individually tailored. Providing access to a consultant with
significant experience in the HIV community gave sites an
opportunity to work through challenges and maintain their
enthusiasm and momentum for the duration of the study.
Because other HIV-focused studies had failed in their efforts
to recruit women and many individuals voiced serious doubts
that GRACE would be able to meet enrollment goals, the focus of the study team and the consultant was first and foremost on recruitment; the shift in focus to patient retention did
not occur until too late in the study. One of the lessons learned
was that retention of women should have been a critical focus
from the initial planning stages of the study.
Planning and conduct of the GRACE study was associated
with slightly higher costs (e.g., additional CRO costs, consulting fees, toolkit costs) and resource requirements (e.g.,
public relations support for media outreach, extensive site
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support) than traditional studies. Collectively, these tactics all
contributed to successful enrollment within the preestablished time frame for the study and were likely worth the
additional investment. Although the individual contributions
of these components cannot be assessed, it is believed that
setting enrollment quotas alone would not have been sufficient to reach the desired enrollment goals, as previous trials
using enrollment quotas have not achieved the same level of
success in enrollment as GRACE. The Safety, efficacy and
Pharmacokinetics of tipRanavir boosted with low-dose ritonavir IN 400 racially and Gender-diverse HIV-positive treatment-experienced population (SPRING) study, for example,
aimed to enroll 200 women and 200 men at 72 sites across
eight countries, including white, black, Hispanic, Asian, and
American-Indian patients. The study was terminated, however, not because of efficacy or safety concerns but because of
poor enrollment.16,17
The higher discontinuation rates seen in women (compared
with men) and blacks (compared with nonblacks) in GRACE
have also been reported in other studies. The Context Study,
which assessed treatment-experienced patients, reported a
discontinuation rate of 47% in women compared with 22% in
men; however, women comprised only 15% of the 315 patients enrolled, limiting the interpretation of these data.9
Additionally, in a study that enrolled 254 patients, including a
high proportion of women (50%), black (40%), and Hispanic
(37%) treatment-naı̈ve patients, Kumar et al.18 reported an
overall discontinuation rate of 49%; specific differences by sex
were not reported. The Women First Study was specifically
designed to assess the efficacy and safety of combination ARV
therapy in protease inhibitor-naı̈ve women and also to evaluate treatment compliance and continued study participation.
Specific support for patients was provided and included labeled pillboxes with dosing schedules, dosing instruction
cards, day planners, and education on HIV and management
of the disease.19 Although ARV treatment was generally well
tolerated in this study, only 22 of the 68 patients enrolled were
available for analysis at week 48.19,20
In GRACE, the rate of discontinuation due to adverse
events was slightly higher for women than men. Although the
difference was not statistically significant, it is possible that
additional women stopped therapy and disappeared from
care (i.e., categorized as ‘‘lost to follow-up’’) for issues related
to tolerability. Indeed, there were subtle differences in tolerability between women and men in GRACE—women experienced more nausea and vomiting, whereas men reported
more diarrhea.14 These findings are supported by other ARV
studies as well.8,10,21 One approach to reducing the rate of
discontinuation in clinical trials may be for healthcare providers to monitor patients more intensively for subtle side
effects, proactively communicate on a regular basis with patients about how they are tolerating treatment, and provide
patients with information about management of side effects if
they occur.
Although more women discontinued from GRACE than
men and more blacks discontinued than nonblacks, discontinuation rates were highly variable by site. Indeed, for at least
one site in the southeastern United States, several black women generally considered to be at high risk for discontinuation successfully completed the study. In such cases, a strong
patient-provider relationship and the dedication of the investigator likely contributed to the patients’ success, enabling
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patients to discuss their concerns and overcome challenges
before they were compelled to discontinue. The impact of
such a relationship cannot be underestimated when it comes
to continued engagement in clinical care or in clinical trial
conduct, and the higher retention rates for novel sites in
GRACE may have hinged on such relationships. Novel sites
tended to be primary care sites and have fewer other active
studies, which likely allowed more focus by the site study
staff on individualized support of the GRACE patients. It is
possible that increased use of primary care sites, whether
experienced in research or not, may be important in improving patient retention in future studies.
The successes and challenges associated with GRACE
provided insight into data gaps that can be addressed in future trials. First, capturing socioeconomic data (such as
housing status, education level, number of dependents, and
income level) from patients and including more psychosocial
measures at baseline may aid in understanding the factors
that influence patients’ motivation to stay in care. In the case
of GRACE, having access to such information may have led to
a clearer understanding of the reasons for study discontinuation and lower response rates among black patients. Second,
collecting information at study entry about intolerance to
prior ARV regimens and rates of treatment failure may provide additional insight into subtle differences that exist
among treatment-experienced patients. Identifying up front
which study participants are predisposed to challenges with
adherence and tolerability may allow study staff to more effectively mitigate the risk of poor adherence or study discontinuation due to intolerance. Third, collecting detailed
information from patients at the time of study discontinuation
would provide more insight than collecting data in the typical
broad categories of ‘‘loss to follow-up’’ and ‘‘noncompliance.’’
In GRACE, specific details related to study discontinuations
would have helped the study sponsor and sites better understand what proportion of discontinuations was preventable and subsequently develop strategies to address the root
causes of discontinuation.
Over the course of GRACE, we identified three main areas
that could have been improved and that we would approach
differently in the future. First, we would place more emphasis
on study retention during study startup and routine study
monitoring. In theory, early identification of discontinuation
trends would allow for earlier intervention, which may allow
for earlier patient-focused efforts (e.g., from the screening
phase forward) to foster retention. Second, more novel study
sites would be enlisted, particularly focusing on sites that
serve as a source of primary care for women. Finally, more
education would be provided around the site grants
and how to use them effectively; many sites did not access
these funds and were unsure of how to put the resources to
best use. Ideally, technical assistance could be provided to
sites to help implement grant-related activities and to support data collection regarding factors contributing to study
discontinuation.
Conclusions
GRACE was the largest study in North America to date to
focus on treatment-experienced women with HIV receiving
ARV therapy. The successes of GRACE were rooted in pretrial
preparation, engagement of community advisors, mandated
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enrollment quotas, choice of study sites, and providing study
sites with the resources and flexibility to adapt practices as
necessary to support patients. These strategies were effective
in the recruitment of underrepresented women of color to the
trial. In one third of the women, however, retention efforts fell
short of overcoming the well-rooted and very real barriers to
continuous healthcare faced by women and other disadvantaged populations. Lessons learned during the planning and
conduct of the GRACE study form a solid foundation for the
development and design of future ARV clinical trials and may
contribute to a better general understanding of how to enroll
and retain diverse populations in clinical trials and care.
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